Drug Approval | July 03, 2023
Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The company has reported total income of Rs. 815.11 crores during the period ended March 31, 2023
Single dose of Ferric Carboxymaltose (FCM) up to 750 mg of iron can be infused in 15 minutes
The certification issued by the EDQM verifies the compliance of pharmaceutical substances
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
The company has reported total income of Rs. 1407.34 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
